VIDEO: Oral TYK2 inhibitor ‘appears to have legs’ for plaque psoriasis

In this Healio exclusive video, Raj Chovatiya, MD, PhD, discussed research into psoriasis from the American Academy of Dermatology Annual Meeting, examining results from the phase 2 STRIDE study.

Chovatiya, clinical associate professor at Chicago Medical School at Rosalind Franklin University and assistant clinical professor at George Washington University School of Health Sciences, discussed the efficacy and safety of the highly selective oral tyrosine kinase 2 (TYK2) inhibitor ESK-001 (Alumis), which Chovatiya said “appears to have legs” in the treatment of mild to severe plaque psoriasis.

“It looks like we can have another entrant into the TYK2 space very soon, and hopefully another really good oral option for our patients that otherwise have generally had a pretty dry pipeline in this day of biologics,” Chovatiya said.